182 related articles for article (PubMed ID: 38159033)
1. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
7. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
8. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
11. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
García E; Ayoub N; Tewari KS
J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
15. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.
Wolford JE; Tewari KS
Expert Opin Drug Discov; 2018 May; 13(5):445-457. PubMed ID: 29463131
[TBL] [Abstract][Full Text] [Related]
16. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
19. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
20. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
